- Research article
- Open Access
- Open Peer Review
Enhanced efficacy of photodynamic therapy by inhibiting ABCG2 in colon cancers
© Kim et al. 2015
- Received: 27 December 2014
- Accepted: 25 June 2015
- Published: 7 July 2015
Photodynamic therapy (PDT) contains a photosensitizing process, which includes cellular uptake of photosensitizer and delivery of light to the target. ATP-binding cassette subfamily G2 (ABCG2) regulates endogenous protoporphyrin levels. In human colon cancers, it is not fully examined the role of ABCG2 in porphyrin-based photodynamic therapy.
SW480 and HT29 cells were selected because they showed low and high ABCG2 expression levels, respectively. Pyropheophorbid-a (PPa) was used as a photosensitizer. Cells were exposed to a 670 nm diod laser. Cell viability and necrosi apoptosis was examined. Production level of singlet oxygen was detected with the photomultiplier-tube s/ -based singlet oxygen detection system.
SW480 cells, which expressed lower level of ABCG2, showed the higher uptake of PPa than HT-29 cells. The uptake level of PPa was significantly correlated with the decreased cell viability after PDT. Pretreatment with a ABCG2 inhibitor, Ko-143, significantly enhanced the PDT efficacy in HT29 cells compared to vehicle-pretreated cells. To confirm the ABCG2 effect on PDT, we established ABCG2 over-expressing stable cells in SW480 cells (SW480/ABCG2). Furthermore, SW480/ABCG2 cells showed significantly decreased PDT effect compared to the control cells. The increased or decreased cell survival was significantly correlated with the production level of singlet oxygen after PDT.
ABCG2 plays an important role in determining the PDT efficacy by controlling the photosensitizer efflux rate. This implies the control of ABCG2 expression may be a potential solution to enhance photosensitivity.
- Photodynamic therapy
- Colon cancer
- ATP-binding cassette transporters
- Photosensitizing agents
Photodynamic therapy (PDT) is a modality that uses a photosensitizer that is selective to target cells, followed by exposure to a given specific light source [1, 2]. Photosensitizer is excited by irradiation, producing reactive oxygen species such as singlet oxygen, other free radicals and cause necrosis or apoptosis of the target cells . PDT is indicated in the treatment of various cancers and is known to be particularly effective in basal cancer cells such as skin cancer .
Pheophorbide a (PPa) is a chlorophyll-based photosensitizer which is localized to the mitochondria . Many studies reported that PPa showed an anti-tumor effect in vivo on human lung, liver, and skin cancer [6–8]. Irradiated PPa produced singlet oxygen which rapidly induced depolarization of mitochondrial membrane potential and tumor cell death. PDT using PPa has been attempted on hepatocarcinoma, Jurkat leukemia cell, pigmented melanoma, and colon cancer cells [9–11]. PPa had structural similarities with porphyrin which was the most commonly used photosensitizer .
The main problem in the chemotherapy of cancer is that drug resistance may occur and such resistance is the main reason that makes cancer treatment difficult. One of the drug resistance mechanisms derived from the drug efflux system of cells. ATP-binding cassette subfamily G2 (ABCG2) is a family of multi-drug resistance proteins, which protect cell from exogenous and endogenous toxin through the efflux system . ABCG2 interacts with heme structure and porphyrins and block their accumulation in cells and tissues [14, 15]. Intracellular uptake of photosensitizer is accordingly regulated by ABC transporter superfamily member ABCG2. ABCG2 was regarded as the main cause of resistance to PDT. Studies with ABCG2 knock-out mice had shown the accumulation of porphyrin photosentizer and increase in photosensitivity compared to wild type mice, which means that the ABCG2 protein plays a major role in PDT efficacy . Also, the overexpression of ABCG2 induced resistance to PDT by blocking the accumulation of photosensitizer in cell . In colon cancers, a study reported that the expression of ABCG2 correlated with the shortened patient survival .
In this study, we hypothesized that ABCG2 is a target protein in enhancing colon cancer PDT efficacy. To confirm our hypothesis, we tested PDT effect depending on ABCG2 expression level. We also checked the results after the inhibition of ABCG2 with Ko-143. In order to show that ABCG2 is directly related with PDT efficacy, we established ABCG2 overexpressing stable cells in SW480 and tested PDT efficacy in vitro. Furthermore, we checked the anti-tumor effect on xenograft model using cells with either low or high expression of ABCG2 cell in vivo. The results from this study show a possible cause of reduced sensitivity to photosensitizer-PDT in colon cancer cells. Inhibition of ABCG2 expression may be a potential solution to enhance photosensitivity.
Pheophorbide a (PPa) was obtained from Frontier Scientific Inc. (USA). Ko-143 and thiazolyl blue tetrazolium bromide (MTT) were from Sigma Aldrich. Mouse monoclonal antibodies to ABCG2 and β-actin were from Santa Cruz (USA). Polyclonal rabbit antibody to caspase (cleaved) was purchased from abcam (UK). Polyclonal rabbit antibody to LC3 was purchased from Cell Signaling Technology (USA).
Cell culture and in vitro photodynamic treatment
SW480, SW480/ABCG2, HT29, HCT116, LoVo, and DLD1 cells were maintained under an atmosphere of 5 % CO2 in RPMI medium (Genedepot, USA) supplemented with 10 % fetal bovine serum and 1 % penicillin-streptomicin (Genedepot, USA). Cells were incubated with or without PPa (0–400 nM) for 16 h at 37 °C in RPMI medium supplemented with 5 % fetal bovine serum and 1 % penicillin-streptomicin. Ko-143 (0-1uM) were pretreated or treated for 1 h at 37 °C. The cells were then photoirradiated using a diod laser emitting red light at 670 nm wavelength (equipment by Kuk-Je A & SL Co., Seoul, Korea). The power density at the illumination area was 800 mW/cm2 and total light dose was 4 J/cm2. Thereafter, cells were harvested at 4 h, 8 h, and 24 h, respectively.
Cell viability assay
Cells were cultured in 96-well culture plates (1 × 104cells/well) overnight. Cells applied to PDT were incubated for 4 h with 0.5 mg/ml thiazolyl blue tetrazolium bromide. Converted MTT formazan crystals were solubilized DMSO. The absorbance at 540 nm was measured using microplate reader (Biotek ELX-800 Absorbance Reader, USA).
Measurement of Singlet oxygen production
Cells were incubated with or without PPa (0–400 nM) for 16 h at 37 °C, washed twice in PBS, and lysed in methanol. Lysed cells were applied to PMT-based singlet oxygen monitoring system (Physical Sciences Inc., USA).
Quantitative Real-time PCR
Total RNA was isolated with Trizol Reagent (Invitrogen, USA) and reverse-transcribed with a reverse transcription (RT)-PCR kit (Takara) according to manufacturer’s instruction. The level of ABCG2 was measured using a MX-3000P (Stratagene, USA). SYBR green master mix (Takara, Japan) was used to quantify the mRNA expression of ABCG2. The primers used for quantitative RT-PCR were as follows: ABCG2 sense, 5’-TGGCTTAGACTCAAGCACAGC; ABCG2 antisense, 5’-TCGTCCCTGCTTAGACATCC-3; GAPDH sense, 5’-AGCCACATCGCTCAGACAC-3’; GAPDH antisense, 5’-GCCCAATACGACCAAATCC-3’.
Cells were cultured on glass coverslip. Glass coverslips of confluent cells were washed with PBS two times. Cells were fixed for 20 min at room temperature in 4 % paraformalaldehyde/PBS. After rinsing with PBS, cells were incubated with 5%FBS/PBS for 30 min to block non-specific staining. After washing with PBS, cells were incubated with ABCG2 antibody in 5%FBS/PBS overnight (1:200). After washing with PBS, cells were incubated with secondary Alexa-488 antibody in 5%FBS/PBS for an hour. Cells were monitored by fluorescence microscopy (Axiovert 200 MAT, Zeiss, Germany).
Cells were applied to PDT and then incubated with Annexin V-FITC or PI for 15 min at room temperature. Measurement of apoptosis or necrosis was done using FACS Calibur flow cytometer (BD Bioscience, USA).
Cells lysed in buffer containing 20 mM HEPES (pH 7.0), 1 % Triton X-100, 150 mM NaCl, 10 % glycerol, 2 mM EGTA, 1 mM EDTA, 1 mM Glycerol 2-phosphate, 1 μg/ml leupeptin, 1 μg/μl aprotinin, 1 mM AEBSF, 50 mM NaF, and 1 mM NA3VO4. The proteins separated by SDS-PAGE were transferred to a nitrocellulose membrane using electrophoresis tank. After the membrane was incubated with specific antibodies, the signal was enhanced with chemiluminesence reagents (Genedepot) and then measured by LAS-3000 Image Analysis System (Fujifilm, Japan).
Stable cell establishment in SW480 cells using retrovirus
For preparation of SW480/ABCG2, retrovirus encoding ABCG2 genes were produced by using BglII/XhoI sites. HEK293T cells were transfected with pMSCV-ABCG2, pgag-pol, and pVSV-G, using Lipofectamine2000, and then 48 h later, media including Prx III retroviruses were collected and filtered to remove cell debris. SW480 cells were incubated with ABCG2 retrovirus, and the cells were inoculated with ABCG2 retrovirus. The cells expressing ABCG2 were selected with puromycin.
Xenograft model and Photodynamic therapy
Four-week-old male BALB/c nude mice were used for in vivo study. The animal experiments were conducted in accordance with the institutional guidelines of the Catholic University of Korea, College of medicine, Seoul, Korea. SW480 and SW480/ABCG2 cells (0.5 × 106) were inoculated subcutaneously in 100 μl of phosphate-buffered saline (PBS). The mice were then divided into a treatment and a control group. The treatment group consisted of two subgroups: the control group and the PDT applied group (670 nm). Animals were injected i.v. with Ko-143(10 mg/kg) followed by i.v. PPa after 1 h.
Data were expressed as means ± standard error of mean (SEM) using Student t test.
Differences of PDT effect derived from PPa accumulation depending on ABCG2 expression level in colon cancer cell
Enhanced efficacy of PDT by ABCG2 inhibition
Effect of ABCG2 overexpression
In vivo antitumor effects of PDT
In this study, we demonstrated that ABCG2 plays a main role in drug resistance related to PDT in colon cancer cell. Our data showed that ABCG2 overexpression strongly induced photosensitizer efflux which means that ABCG2 inhibition may be the solution of drug resistance in colon cancer. Studies indicated that ABCG2 contributes to protection of cellular accumulation of porphyrin and toxic heme components . ABCG2 was first discovered in a breast cancer cell line, which is also called breast cancer resistance protein (BCRP/ABCG2) . It has been reported that ABCG2 overexpression using temporarily ABCG2-transfected HEK293 cells showed decreased cellular accumulation of PPIX, whereas other ABC-transporter overexpression (ABCB1 and ABCC1) did not effect on PPIX accumulation, which suggested that ABCG2 could be the main target of drug resistance . In human colon cancer cell, ABCG2 is known as main cause of resistance to drug such as SN-38 which is used for chemotherapy in colon cancer . ABCG2 is important in developing drug resistance in PDT. However, the association ABCG2 and PDT efficacy in colon cancer cell remain unclear. Our studies demonstrate that PDT efficacy is regulated by ABCG2 expression level in colon cancer. First of all, we checked the ABCG2 expression level in mRNA and protein. We found that high expression level of ABCG2 cells showed low efficacy of PDT which was resulted from low accumulation PPa due to ABCG2 induced efflux. Fluorescence microscopy experiments also showed low level of PPa in ABCG2 overexpressed cell. Also, ABCG2 inhibitor, Ko-143, treated cell showed increased PPa accumulation, which induced high PDT efficacy. Consistently, ABCG2 knock-down in HT-29 using siRNA showed increased PPa (data not shown). PDT efficacy was correlated with ABCG2 expression level. SW480/ABCG2 expressing high level of ABCG2 showed no apoptosis or necrosis after PDT, whereas, SW480 cells were prone to apoptosis or necrosis. These phenomena were also confirmed by higher level of cleaved caspase-3 and LC3II in SW480 cells. SW480 treated with PDT showed increased cleaved caspase-3 and LC3II compared to SW480/ABCG2, which means that apoptotic and autophagic cell death was induced in SW480 cells. Tumor cell death in PDT was induced by the release of singlet oxygen produced by photo-excitation of photosensitizer by visible light . We found that singlet oxygen production was correlated with PPa accumulation in cells. These data suggested that PDT efficacy was dependent on PPa accumulation and PPa induced singlet oxygen production. According to recent report, ABCG2, drug transporter, regulates the outcome of hypericin-mediated photodynamic therapy in HT-29 .
ABCG2 has been already found to have the main role in porphyrin accumulation in mice. To show ABCG2 directly influenced PDT efficacy, we established SW480 stably overexpressing ABCG2 and also tested PDT efficacy using in vitro system, and then we checked the anti-tumor effect on xenograft model using cells differently expressing ABCG2 in vivo studies. The tumor size of SW480 cells was significantly smaller in the group treated with PPa-PDT compared to the SW480/ABCG2 injected group. These results indicate that antitumor effects are dependent on ABCG2 expression level.
Many researchers reported that ABCG2 inhibition had decreased PDT efficacy through other protein regulation [25–27]. However, we directly showed ABCG2 effect in colon cancer cell using ABCG2 overexpressed cell line both in vitro and in vivo, providing direct evidences of enhanced PDT effect when inhibiting the ABCG2. In this aspect, our research suggests a very important role of ABCG2 in drug resistance and PDT efficacy in colon cancer cell, and provides reasonable and sufficient evidence to develop ABCG2 inhibitor for protecting drug resistance.
In summary, this study shows a possible cause of reduced sensitivity to photosensitizer-PDT in colon cancer cells. Our study provides a potential solution to enhance photosensitivity by inhibition of ABCG2 expression.
This study was supported by the Global Research and Development Center. The funding of this foundation comes from the National Research Foundation of Korea through the Ministry of Science, ICT and Future Planning (NRF-2011-0031644).
This research was supported by program of Global Research and Development Center through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2011-0031644).
- Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3(5):380–7.View ArticlePubMedGoogle Scholar
- Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer. 2006;6(7):535–45.View ArticlePubMedPubMed CentralGoogle Scholar
- Oleinick NL, Morris RL, Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci. 2002;1(1):1–21.View ArticlePubMedGoogle Scholar
- Choudhary S, Nouri K, Elsaie ML. Photodynamic therapy in dermatology: a review. Lasers Med Sci. 2009;24(6):971–80.View ArticlePubMedGoogle Scholar
- Tang PM, Liu XZ, Zhang DM, Fong WP, Fung KP. Pheophorbide a based photodynamic therapy induces apoptosis via mitochondrial-mediated pathway in human uterine carcinosarcoma. Cancer Biol Ther. 2009;8(6):533–9.View ArticlePubMedGoogle Scholar
- Chan JY, Tang PM, Hon PM, Au SW, Tsui SK, Waye MM, et al. Pheophorbide a, a major antitumor component purified from Scutellaria barbata, induces apoptosis in human hepatocellular carcinoma cells. Planta Med. 2006;72(1):28–33.View ArticlePubMedGoogle Scholar
- Yin X, Zhou J, Jie C, Xing D, Zhang Y. Anticancer activity and mechanism of Scutellaria barbata extract on human lung cancer cell line A549. Life Sci. 2004;75(18):2233–44.View ArticlePubMedGoogle Scholar
- Nakamura Y, Murakami A, Koshimizu K, Ohigashi H. Inhibitory effect of pheophorbide a, a chlorophyll-related compound, on skin tumor promotion in ICR mouse. Cancer Lett. 1996;108(2):247–55.View ArticlePubMedGoogle Scholar
- Lee WY, Lim DS, Ko SH, Park YJ, Ryu KS, Ahn MY, et al. Photoactivation of pheophorbide a induces a mitochondrial-mediated apoptosis in Jurkat leukaemia cells. J Photochem Photobiol B. 2004;75(3):119–26.View ArticlePubMedGoogle Scholar
- Hajri A, Wack S, Meyer C, Smith MK, Leberquier C, Kedinger M, et al. In vitro and in vivo efficacy of photofrin and pheophorbide a, a bacteriochlorin, in photodynamic therapy of colonic cancer cells. Photochem Photobiol. 2002;75(2):140–8.View ArticlePubMedGoogle Scholar
- Jin ZH, Miyoshi N, Ishiguro K, Umemura S, Kawabata K, Yumita N, et al. Combination effect of photodynamic and sonodynamic therapy on experimental skin squamous cell carcinoma in C3H/HeN mice. J Dermatol. 2000;27(5):294–306.View ArticlePubMedGoogle Scholar
- Robey RW, Steadman K, Polgar O, Bates SE. ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy. Cancer Biol Ther. 2005;4(2):187–94.View ArticlePubMedGoogle Scholar
- Ishikawa T, Nakagawa H, Hagiya Y, Nonoguchi N, Miyatake S, Kuroiwa T. Key Role of Human ABC Transporter ABCG2 in Photodynamic Therapy and Photodynamic Diagnosis. Adv pharmacol Sci. 2010;2010:587306.PubMedPubMed CentralGoogle Scholar
- Krishnamurthy P, Xie T, Schuetz JD. The role of transporters in cellular heme and porphyrin homeostasis. Pharmacol Ther. 2007;114(3):345–58.View ArticlePubMedGoogle Scholar
- Wakabayashi K, Tamura A, Saito H, Onishi Y, Ishikawa T. Human ABC transporter ABCG2 in xenobiotic protection and redox biology. Drug Metab Rev. 2006;38(3):371–91.View ArticlePubMedGoogle Scholar
- Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A. 2002;99(24):15649–54.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang X, Xia B, Liang Y, Peng L, Wang Z, Zhuo J, et al. Membranous ABCG2 expression in colorectal cancer independently correlates with shortened patient survival. Cancer Biomark. 2013;13(2):81–8.PubMedGoogle Scholar
- Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther. 2002;1(6):417–25.PubMedGoogle Scholar
- Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995;376(6535):37–43.View ArticlePubMedGoogle Scholar
- Codogno P, Meijer AJ. Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ. 2005;12 Suppl 2:1509–18.View ArticlePubMedGoogle Scholar
- Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48–58.View ArticlePubMedGoogle Scholar
- Yamazaki R, Nishiyama Y, Furuta T, Hatano H, Igarashi Y, Asakawa N, et al. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. Mol Cancer Ther. 2011;10(7):1252–63.View ArticlePubMedGoogle Scholar
- Mroz P, Yaroslavsky A, Kharkwal GB, Hamblin MR. Cell death pathways in photodynamic therapy of cancer. Cancers. 2011;3(2):2516–39.View ArticlePubMedPubMed CentralGoogle Scholar
- Sackova V, Kulikova L, Mikes J, Kleban J, Fedorocko P. Hypericin-mediated photocytotoxic effect on HT-29 adenocarcinoma cells is reduced by light fractionation with longer dark pause between two unequal light doses. Photochem Photobiol. 2005;81(6):1411–6.View ArticlePubMedGoogle Scholar
- Choi BH, Ryoo IG, Kang HC, Kwak MK. The sensitivity of cancer cells to pheophorbide a-based photodynamic therapy is enhanced by Nrf2 silencing. PLoS One. 2014;9(9), e107158.View ArticlePubMedPubMed CentralGoogle Scholar
- Jendzelovsky R, Mikes J, Koval J, Soucek K, Prochazkova J, Kello M, et al. Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells. Photochem Photobiol Sci. 2009;8(12):1716–23.View ArticlePubMedGoogle Scholar
- Jung KA, Choi BH, Kwak MK. The c-MET/PI3K signaling is associated with cancer resistance to doxorubicin and photodynamic therapy by elevating BCRP/ABCG2 expression. Mol Pharmacol. 2015;87(3):465–76.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.